 In the United States , the indications for linezolid use approved by the U.S. Food and Drug Administration ( FDA ) are the treatment of vancomycin @-@ resistant Enterococcus faecium infections , with or without bacterial invasion of the bloodstream ; nosocomial pneumonia ( hospital @-@ acquired ) and community @-@ acquired pneumonia caused by S. aureus or S. pneumoniae ; complicated skin and skin structure infections ( <unk> ) caused by susceptible bacteria , including diabetic foot infection , unless complicated by osteomyelitis ( infection of the bone and bone marrow ) ; and uncomplicated skin and soft tissue infections caused by S. pyogenes or S. aureus . The manufacturer advises against the use of linezolid for community @-@ acquired pneumonia or uncomplicated skin and soft tissue infections caused by MRSA . In the United Kingdom , pneumonia and <unk> are the only indications noted in the product labeling . 
